J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 11, Number 5, May 2019, pages 321-325

External Validation of the LabBM Score in Patients With Brain Metastases

Figure

Figure 1. Actuarial overall survival stratified by LabBM score (0 - 1 point: median 4.0 months; 1.5 - 2 points: median 2.9 months; > 2 points: median 1.5 months; P = 0.0001 (best vs. intermediate and best vs. worst group), P = 0.046 (intermediate vs. worst group)).

Tables

**Table 1.** Patient Characteristics
Baseline parameters	Number	Percent
Non-small cell lung cancer	75	45
Small cell lung cancer	8	5
Breast cancer	34	20
Malignant melanoma	23	14
Renal cell cancer	9	5
Colorectal cancer	7	4
Other or unknown primary tumors	11	7
Extracranial metastases	141	84
No extracranial metastases	26	16
Controlled primary tumor	108	65
Uncontrolled primary tumor	59	35
Female gender	93	56
Male gender	74	44
Incomplete whole-brain radiotherapy	6	4
Systemic therapy after whole-brain radiotherapy	92	55
LabBM score > 2	13	8
LabBM score 1.5 - 2.0	46	28
LabBM score 0 - 1.0	108	65
Low albumin	17	10
Low hemoglobin	52	31
Low platelets	2	1
High C-reactive protein	51	31
High lactate dehydrogenase	71	43

**Table 2.** Comparison Between the Three Datasets That Were Used to Develop and Validate the LabBM Score
Dataset	Vienna	Zurich	Bodo
SRS: stereotactic radiosurgery; WBRT: whole-brain radiotherapy. *Percentage for 1,200 and 366 patients, respectively (not all had complete blood tests available).
Number of patients	815	199	167
Treatment	45% surgery, 36% SRS*	83% surgery*	100% WBRT
0 - 1 point	33%	55%	65%
1.5 - 2 points	37%	31%	28%
2.5 - 3.5 points	30%	15%	8%
Median survival, months
Class 1	11	10	4
Class 2	7	6	3
Class 3	3	1	1.5